Wall Street Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wall Street Associates’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,800	Closed	-$336K	–	314
2015 Q2	$336K	Hold	2,800	–	–	0.03%	306
2015 Q1	$292K	Sell	2,800 -702	-20%	-$71.1K	0.03%	303
2014 Q4	$340K	Sell	3,502 -1,708	-33%	-$158K	0.03%	286
2014 Q3	$407K	Buy	+5,210	New	+$336K	0.04%	265

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Wall Street Associates's ALNY Position: Q3 2015 in Review

Wall Street Associates sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2015, closing a stake of 2,800 shares — an estimated $336K sold.

Wall Street Associates first reported a position in ALNY in Q3 2014 and held it in 4 quarters. The position peaked at $407K in Q3 2014. 258 funds tracked by Wall St. Rank hold ALNY as of Q3 2015.

Wall Street Associates reported no remaining Alnylam Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Wall Street Associates sold 2,800 Alnylam Pharmaceuticals shares in Q3 2015, an estimated $336K.
Wall Street Associates first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Wall Street Associates's Alnylam Pharmaceuticals position peaked at $407K in Q3 2014.
258 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2015.

Based on Wall Street Associates's 13F filing for Q3 2015, filed 12 Nov 2015.